CD4 and graft versus host disease: PT-Cy is highly effective in preventing GVHD by modulating alloreactive T cell responses, i.e. reducing proliferation of CD4 + T cells, depleting activated CD4+ and CD8+ effector T cells and promoting CD4+ regulatory T cell recovery, and thereby promoting tolerance [7, 8].